Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-11-15

FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA issued a supplemental approval for Kaletra (lopinavir/ritonavir) submitted by AbbVie.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kaletra (lopinavir)

Snippet

SUPPL AP for KALETRA (LOPINAVIR AND RITONAVIR)